Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab vs Investigator's Choice in Previously Untreated Follicular Lymphoma
NCT06091254Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Feb 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of odronextamab in follicular lymphoma (FL) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Dose-Limiting Toxicities at 35 days, Incidence of Treatment-Emergent Adverse Events at 2 years and 2 more. Started Dec 2023; status: recruiting.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06091254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091254.